Matinas BioPharma (MTNB) Sees Strong Trading Volume
Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) shares saw unusually-high trading volume on Friday . Approximately 4,908,119 shares were traded during mid-day trading, an increase of 304% from the previous session’s volume of 1,214,606 shares.The stock last traded at $1.30 and had previously closed at $1.20.
Separately, Roth Capital initiated coverage on Matinas BioPharma in a research report on Monday, February 11th. They issued a “buy” rating and a $4.75 price objective for the company.
Several institutional investors have recently bought and sold shares of MTNB. Renaissance Technologies LLC grew its position in shares of Matinas BioPharma by 325.6% during the 3rd quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock worth $124,000 after buying an additional 103,200 shares during the period. Virtu Financial LLC acquired a new position in shares of Matinas BioPharma during the 4th quarter worth about $39,000. IFP Advisors Inc grew its position in shares of Matinas BioPharma by 222.0% during the 4th quarter. IFP Advisors Inc now owns 1,775,000 shares of the company’s stock worth $1,083,000 after buying an additional 1,223,828 shares during the period. BlackRock Inc. grew its position in shares of Matinas BioPharma by 147.1% during the 4th quarter. BlackRock Inc. now owns 290,589 shares of the company’s stock worth $173,000 after buying an additional 173,005 shares during the period. Finally, Private Advisor Group LLC grew its position in shares of Matinas BioPharma by 100.4% during the 4th quarter. Private Advisor Group LLC now owns 49,850 shares of the company’s stock worth $30,000 after buying an additional 24,978 shares during the period.
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.
Further Reading: Stock Selection – What is cash flow?
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.